Cline Scientific, a Swedish life science company developing a novel regenerative medicine, and NecstGen, a CDMO and center of excellence for cell and gene therapy, have signed a letter of intent to develop and manufacture clinical batches of Cline’s cell therapy for cartilage repair, StemCART. Under terms of the partnership, NecstGen will support the further development and manufacture of Cline’s cell therapy for damaged cartilage, StemCART. StemCART is an Advanced Therapy Medicinal Product (...